BaseSpace
Correlation
Engine-Public
Sign In
Register
Correlation Engine 2.0
Home
My Data
Bookmarks
Collaborations
Inbox
Import Your Data
QuickView
FAQ
What is QuickView?
What can my QuickView results tell me?
What are the sources for the General Info tab in QuickView?
More QuickView FAQs
Back to top
QuickView
Curated
Studies
Body
Atlas
Disease
Atlas
Pharmaco
Atlas
Knockdown
Atlas
Genetic
Markers
Pathway
Enrichment
Literature
Clinical
Trials
0
Meta-
Analysis
QuickView
Search sequence regions
(e.g.
Acetaminophen
,
rs3825942
,
TGFB1
,
Fatty acid metabolic process
,
Influenza
,
Kidney
)
Organisms
Chromosomes
Start
Stop
Homo Sapiens
Mus Musculus
Rattus Norvegicus
C. Elegans
D. Melanogaster
Saccharomyces Cerevisiae
QuickView
Go back to main search
Bookmark
Forward
QuickView
for
MSLN
(gene)
Summary
General Info
Body Atlas
Most Correlated Tissues
No tissues found
Explore Body Atlas Results
Disease Atlas
Most Correlated Diseases
Loading...
Explore Disease Atlas Results
Pharmaco Atlas
Most Correlated Compounds
Loading...
Explore Pharmaco Atlas Results
Knockdown Atlas
Most Correlated Gene Perturbations
Loading...
Explore Knockdown Atlas Results
Curated Studies
Most Correlated Studies
CD4+ T cells expressing chimeric antigen receptors (CAR) against mesothelin; varying signal domains
CD8+ T-cells from PBMCs of normal donors engineered with M5 CAR+ & activated MSLN+ AsPc-1 cells
Explore Curated Studies Results
Literature
Most Relevant Literature
Mesothelin expression in gynecologic carcinosarcoma: clinicopathological significance and correlatio…
Specific Targeting of Mesothelin-Expressing Malignant Cells Using Nanobody-Functionalized Magneto-Fl…
Mesothelin Secretion by Pancreatic Cancer Cells Co-opts Macrophages and Promotes Metastasis.
Targeting Mesothelin in Solid Tumours: Anti-mesothelin Antibody and Drug Conjugates.
Mesothelin antigen density influences anti-mesothelin chimeric antigen receptor T cell cytotoxicity.
Explore Literature Results
Clinical Trials
Most Relevant Clinical Trials
CD40 Ligand Expressing MSLN-CAR T Cell Therapy in MSLN Positive Advanced/Metastatic Solid Tumors
MSLN STAR-T Cells in the Treatment of Advanced Malignant Solid Tumors
αPD1-MSLN-CAR T Cells for the Treatment of MSLN-positive Advanced Solid Tumors
αPD1-MSLN-CAR T Cells for the Treatment of MSLN-positive Advanced Solid Tumors
αPD1-MSLN-CAR T Cells for the Treatment of MSLN-positive Advanced Solid Tumors
Explore Clinical Trials Results
search
→
result
search
→
result
See more about this page
See complete FAQ